Over 47 million Americans have a “silent” build-up of amyloid plaques—high levels of amyloid plaques without any memory loss or cognitive impairments. Neurologists call this preclinical Alzheimer’s disease. With new FDA-approved drugs like donanemab and…
![](https://www.sermo.com/wp-content/uploads/2024/07/alzheimer-survey-blog-img-720x405.jpg)